Teva Pharmaceuticals and Medincell said the U.S. Food and Drug Administration has accepted Teva’s New Drug Application for TEV-’749, an investigational once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of schizophrenia in adults. The application is supported by Phase 3 SOLARIS trial results, and TEV-’749 uses Medincell’s SteadyTeq copolymer technology for sustained drug release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260220354072) on February 20, 2026, and is solely responsible for the information contained therein.